Xtandi ® (enzalutamide) – New formulation approval
August 4, 2020 - The FDA approved Astellas’ Xtandi (enzalutamide) tablets, for the treatment of patients with castration-resistant prostate cancer or metastatic castration-sensitive prostate cancer.
Download PDF
